Pacific Biosciences of California, Inc. (NASDAQ:PACB) – Equities research analysts at First Analysis increased their Q3 2017 earnings per share (EPS) estimates for Pacific Biosciences of California in a research report issued to clients and investors on Thursday. First Analysis analyst now forecasts that the biotechnology company will earn ($0.18) per share for the quarter, up from their prior forecast of ($0.22). First Analysis also issued estimates for Pacific Biosciences of California’s Q4 2017 earnings at ($0.17) EPS, FY2017 earnings at ($0.87) EPS, Q1 2018 earnings at ($0.19) EPS and FY2018 earnings at ($0.69) EPS.

Several other research firms have also recently commented on PACB. Cantor Fitzgerald set a $8.00 target price on shares of Pacific Biosciences of California and gave the stock a “buy” rating in a research note on Thursday, April 27th. Zacks Investment Research raised shares of Pacific Biosciences of California from a “sell” rating to a “hold” rating in a research note on Wednesday, April 12th. BidaskClub raised shares of Pacific Biosciences of California from a “strong sell” rating to a “sell” rating in a research note on Tuesday. Finally, ValuEngine cut shares of Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a research note on Tuesday, June 13th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a buy rating to the stock. Pacific Biosciences of California presently has a consensus rating of “Hold” and an average target price of $10.00.

COPYRIGHT VIOLATION NOTICE: “Q3 2017 Earnings Forecast for Pacific Biosciences of California, Inc. Issued By First Analysis (NASDAQ:PACB)” was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.dailypolitical.com/2017/08/09/q3-2017-earnings-forecast-for-pacific-biosciences-of-california-inc-issued-by-first-analysis-nasdaqpacb.html.

Pacific Biosciences of California (NASDAQ:PACB) opened at 4.14 on Monday. Pacific Biosciences of California has a 12-month low of $3.08 and a 12-month high of $9.50. The firm’s market capitalization is $403.07 million. The company has a 50-day moving average price of $3.45 and a 200-day moving average price of $4.26.

Pacific Biosciences of California (NASDAQ:PACB) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.02. Pacific Biosciences of California had a negative net margin of 89.67% and a negative return on equity of 93.31%. The business had revenue of $20.07 million during the quarter, compared to analyst estimates of $23.34 million. During the same quarter in the prior year, the company posted ($0.21) earnings per share. The company’s revenue was down 3.2% on a year-over-year basis.

Hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can boosted its stake in shares of Pacific Biosciences of California by 601.5% in the first quarter. Bank of Montreal Can now owns 41,359 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 35,463 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Pacific Biosciences of California during the first quarter valued at about $368,000. SG Americas Securities LLC boosted its stake in shares of Pacific Biosciences of California by 38.1% in the first quarter. SG Americas Securities LLC now owns 89,683 shares of the biotechnology company’s stock valued at $464,000 after buying an additional 24,730 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of Pacific Biosciences of California by 1.1% in the fourth quarter. Teachers Advisors LLC now owns 826,565 shares of the biotechnology company’s stock valued at $3,141,000 after buying an additional 8,774 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Pacific Biosciences of California by 204.3% in the first quarter. Gilder Gagnon Howe & Co. LLC now owns 3,618,977 shares of the biotechnology company’s stock valued at $18,710,000 after buying an additional 2,429,528 shares in the last quarter. 55.42% of the stock is owned by institutional investors.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.

Earnings History and Estimates for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California Inc. and related companies with MarketBeat.com's FREE daily email newsletter.